anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Aspiration of food or liquids can result in suffocation, evolving in coughing, difficulty breathing and forced exhalation. Asphyxia occurs when the aspirated material occludes the upper airways, either in the proximal or distal tract, resulting in the inability to breathe. The risk of asphyxiation death, is increased if a person makes sudden movements while eating, walks or runs while eating, or even becomes distracted or frightened. It is higher in individuals with neurological diseases, intellectual disability (ID), cognitive impairment, psychiatric pathologies or their pharmacological treatments and people carrying additional physiological impairments, which can cause oral dysfunction and dysphagia. Protective mechanisms may sometimes lack or fail to expel food fragments stuck in the airways, which completely obstruct them.
CASE SERIES: The authors present some peculiar cases of subjects who died from food bolus choking, namely a case of mozzarella-cheese clogging in a young subject (25 years old) undergoing rehabilitation treatment following a stroke; a 38-year-old man with middle-grade mental retardation died from first airway food bolus (mush of bread) clogging; a 26-year-old subject with epilepsy died from tripe clogging in the course of a seizure; a 38-year-old subject in psychiatric treatment for depressive disorder who died from clogging with octopus tentacles.
CONCLUSION: Food bolus clogging asphyctic deaths generally occur in subjects with psychic/neurological pathologies, resulting in altered deglutition mechanisms or lack of protective reflexes. Foodstuff, especially if large or viscous, obstruct the proximal or distal airways, leading to acute respiratory failure and death. Autopsy is diriment in ascertain the cause of death.
PURPOSE: To obtain an ultraviolet absorbing agent containing amethoflavone existing in NANTENJITSU (fruit of Nandina domestica) in high concentration as an active component, exhibiting excellent ultraviolet absorbing action in both ultraviolet A and B regions and having high safety and to prepare a cosmetic containing the absorbing agent. CONSTITUTION: This ultraviolet absorbing agent composed of amethoflavone expressed by the formula is produced by adding 1-20 pts. of a polar solvent to 1 pt. of NANTENJITSU and extracting at room temperature or by heating at a temperature near the boiling point of the solvent. The cosmetic containing the ultraviolet absorbing agent protects the skin from ultraviolet rays. The content of the ultraviolet absorbing agent is 0.01-10wt.% based on the total cosmetic. The cosmetic has excellent safety and is continuously usable over a long period. Amethoflavone has absorptions in both ultraviolet A and B regions. The percent absorption of the absorption peak (at 337nm) in the ultraviolet A region is as high as 700 and the agent is suitable as an ultraviolet absorbing agent.
The invention provides porcine parvovirus, vaccine composition and application thereof, and belongs to the technical field of biology. The microbial preservation number of the porcine parvovirus PPV-JS strain is CGMCC (China General Microbiological Culture Collection Center) No.6605. The vaccine composition provided by the invention comprises an inactivated porcine parvovirus PPV-JS strain and veterinary pharmaceutically acceptable adjuvant. The invention also provides the application of the porcine parvovirus PPV-JS strain in preparing medicaments for preventing diseases caused by porcine parvovirus. The porcine parvovirus PPV-JS strain has excellent immunogenicity, and can be used as an activated vaccine production strain and a virus seed for inspection. The vaccine composition (porcine parvovirus inactivated vaccine) provided by the invention is good in safety, high in immune efficacy and long in immunity period, and only requires single dose, so that manpower and side effect of the vaccine to a target animal can be greatly reduced.
The present invention discloses an anticancer medicine composition. The present invention aims to provide an anticancer medicine having the advantages of small toxicity and good therapeutic effect. The anti-cancer medicine composition contains dipyridamole and Beta[4.8]-carotene. Compared with the existing anticancer medicines, comprising chemotherapy medicines, etc., the anticancer medicine composition has the characteristics and advantages that the anticancer medicine composition has small toxicity and no obvious adverse reaction, which is rare in the existing anticancer medicines; the anticancer medicine composition has good therapeutic effect and a 40% to 96% tumor suppression ratio to a lung cancer, a gastric cancer and an ovarian cancer of people; and the anticancer medicine composition has broad-spectrum anticancer activity and has suppression action of different degrees to multiple malignant tumors. Besides, a main dosing path of the anticancer medicine composition is oral taking of a capsule preparation, so the anticancer medicine composition has the advantages of convenient dosing use and high security; people can take in families and in journey. Therefore, the anticancer medicine composition has a wide application prospect.
Globally, the elderly population is increasing, along with a significant rise in the prevalence of chronic conditions such as obesity, hypertension (HT) and type 2 diabetes (T2D). The World Health Organization (WHO) reported in 2021 that over 2 billion adults were overweight, with more than 800 million classified as obese. At the same time, HT affected 1.28 billion adults globally, and the incidence of T2D surged from 108 million in 1980 to 537 million in 2021. Focusing on the older population, recent studies show that around 50% of older adults are affected by obesity, approximately 52.9% suffer from HT, and about 27.5% have T2D. The high prevalence of chronic diseases among older adults poses a significant health challenge and strains healthcare systems globally. This challenge is driven by increased life expectancy and the rapid aging of the population, which together lead to a larger elderly population and, consequently, a higher incidence of chronic diseases.

Obesity, T2D, and HT can lead to complications in the cardiovascular and musculoskeletal systems, which in turn are likely to negatively affect PA, functional capacity, and QoL. For instance, obesity can increase the load on joints due to excessive weight, thereby restricting mobility, while T2D may adversely affect walking capacity through peripheral neuropathy and vascular complications. Hypertension could exacerbate symptoms during PA by increasing the cardiovascular load. In managing chronic diseases such as obesity, HT, and T2D, medications play a vital role in controlling these conditions and preventing complications. Nevertheless, even with this treatment, patients may continue to experience declines in functional capacity, PA, and QoL. The impact of chronic diseases such as obesity, HT, and T2D on PA, functional capacity, and QoL in older adults remains unclear in the literature. Although early detection and prevention of these conditions are important, the specific effects on these health aspects are not well-defined. Research indicates that while these conditions can influence health, their impact varies among individuals, and effective management may mitigate some adverse effects. Further research is needed to clarify how chronic diseases such as obesity, HT, and T2D affect PA, functional capacity, and QoL in the older population, as there remains a significant gap in empirical data regarding these effects.

Therefore, the aim of our study is to compare PA, functional capacity, and QoL between patients with obesity, HT, T2D, and healthy controls, and to elucidate the differing impacts of these chronic conditions on these parameters. The physical activity level will be evaluated using the short form of the International Physical Activity Questionnaire (IPAQ), the functional capacity will be evaluated using the 6-minute walk test, and the quality of life will be evaluated using the SF-36 Quality of Life Scale. At the end of the study, physical activity, functional capacity and quality of life will be compared between older patients with chronic comorbidities and healthy peers.
Subjects randomized 8:2 (active:placebo) to receive two 25 mg capsules of IDX184 per day for 3 days. Fourteen days after treatment, subjects were offered a course of pegylated interferon and ribavirin according to local standard of care.
The use of non-pharmacological applications such as virtual reality, and bubbles are recommended in intravenous interventions. There are very few studies evaluating the effect of non-pharmacological applications in intravenous localization. This study was planned as a randomized controlled trial. The effects of virtual reality and bubble application on pain, fear, anxiety, procedure time, and crying time in intravenous insertion were evaluated. Children (105) aged 6-12 years who were treated in a children's hospital and underwent intravenous placement were randomized to virtual reality, bubbles, and control groups. Distraction techniques such as asking questions and talking were used with the children in the control group. Study data were collected using the Child Anxiety Scale-Conditioning (CAS-D), Child Fear Scale, and Visual Analogue Scales (VAS).

Virtual reality: The child was given a comfortable position. A nurse independent from the study assessed the child with the Child Anxiety Scale-Condition (CAS-D), Child Fear Scale, and Visual Analogue Scale (VAS) before the procedure. The child was fitted with virtual reality goggles and a video of the child's choice was shown. One of the videos was a video of visiting animals in the zoo, while the other video was an aquarium video containing colorful fish and creatures under the sea. The zoo visit video is 3 minutes 51 seconds and the aquarium visit video is 11 minutes 55 seconds. Two minutes after the child started watching the video, peripheral catheter insertion was started. During the procedure, the same nurse, who was independent of the study, assessed the child with the Child Anxiety Scale-Condition(CAS-D), Child Fear Scale, and Visual Analogue Scale (VAS) and recorded the duration of the procedure and the child's crying (how many seconds it lasted)

Bubbles: The child was given a comfortable position. A nurse independent from the study assessed the child with the Child Anxiety Scale-Condition(CAS-D), Child Fear Scale, and Visual Analogue Scale (VAS) before the procedure. The child was given a colorful, lighted bubble gun. Two minutes after the child used the colored-light bubble gun, peripheral catheter insertion was started. During the procedure, the same nurse, who was independent of the study, assessed the child with the Child Anxiety Scale-Condition (CAS-D), Child Fear Scale, and Visual Analogue Scale (VAS) and recorded the duration of the procedure and the child's crying (how many seconds it lasted).

Control: The child was given a comfortable position. A nurse independent from the study assessed the child with the Child Anxiety Scale- Condition (CAS-D), Child Fear Scale, and Visual Analogue Scale (VAS) before the procedure. Peripheral catheter insertion was started. Distraction techniques such as asking questions and talking were used during the procedure. During the procedure, the same nurse, who was independent of the study, evaluated with the Child Anxiety Scale- Condition (CAS-D), Child Fear Scale, and Visual Analogue Scale (VAS) and recorded the duration of the procedure and the crying status of the child (how many seconds it lasted).
FIELD: cosmetics. SUBSTANCE: cream contains texturizing emulsifier, texturizing component, film-forming component, oil phase, distilled glycerine or propylenglycol, vitamin E, bioadditives, triethanolamine, ethyl rectified alcohol of the highest purification, conserving agents, perfume composition, water; additionally cream has allantoin, carbopole or carbomer, or sakap or Sakap-P. The cream is quickly absorbed without fat marks. When cream is used regularly, nails stratification is ceased and they resume hardness and strength. EFFECT: higher moistening and regenerating action. 1 cl, 1 tbl
BACKGROUND: Microvascular invasion (MVI) is a risk factor for postoperative recurrence of hepatocellular carcinoma (HCC), even in early-stage HCC. In small HCC ≤ 3 cm, treatment options include anatomical resection or non-anatomical resection, and MVI has a major effect on treatment decisions. We aimed to identify the predictors of MVI in small HCC ≤ 3 cm.
METHODS: We retrospectively studied 129 patients with very early or early-stage HCC ≤ 3 cm who had undergone 18F-fluorodeoxyglucose positron emission tomography/computed tomography and subsequent hepatic resection from January 2016 to August 2023. These patients were divided into the derivation cohort (n = 86) and validation cohort (n = 43). We examined the risk factors for MVI using logistic regression analysis, and established a predictive scoring system in the derivation cohort. We evaluated the accuracy of our scoring system in the validation cohort.
RESULTS: In the derivation cohort, a Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein (AFP-L3), prothrombin induced by vitamin K deficiency or antagonist-II (PIVKA-II), and metabolic tumor volume (MTV) were independent predictors of MVI. We established the scoring system using these three factors. In the validation test, there were no MVI-positive cases with a score of 0 and 1, and all cases were MVI-positive with a score of 4. Moreover, with a score ≥ 2, the sensitivity, specificity, and accuracy of our scoring system were 100%, 71.4%, and 81.4%, respectively.
CONCLUSIONS: Our scoring system can accurately predict MVI in small HCC ≤ 3 cm, and could contribute to establishing an appropriate treatment strategy.
The global HIV/AIDS epidemic continues to increase at unacceptably high levels, and there is not yet an effective prevention method for HIV infection. This study will test the safety and immune responses of a preventive HIV vaccine, VRC-HIVDNA009-00-VP, which is a multiclade HIV-1 DNA plasmid vaccine.

This study will seek to enroll 30 participants, randomly assigning 15 participants each to the study vaccine arm and the placebo vaccine arm. Three doses of the vaccine will be given by intramuscular (IM) injection using the Biojector 2000 needle-free injection management system: the first dose at Day 0 (entry), second dose at Day 28 (within 7 days before or after Day 28), and third dose at Day 56 (within 7 days before or after Day 56). Participants will attend two screening visits and visits at Days 0 (entry), 2, 14, 28, 30, 42, 56, 58, 70, 84, 168, 252, and 336. At most visits, participants will give a medical history and undergo a physical exam, blood draw, and urine collection. For women, a pregnancy test will be given at each study injection visit. Participants also will be instructed to maintain a diary of local and systemic reactions for 7 days after each injection. They also will be provided with a ruler to measure erythema, induration, or other observable reactions and a thermometer to record temperature on a daily basis.
The invention comprises tetracycline derivatives of the general formula <FORM:1115656/C2/1> wherein R1 and R2 each represent a methyl group, or together represent a pentamethylene residue, and the non-toxic pharmaceutically acceptable salts thereof.  Suitable salts are those of the acids: sulphuric; hydrochloric; nitric; phosphoric; sulphamic; tartaric; hydrobromic; hydriodic; glycolic; citric; maleic; succinic; acetic; ascorbic; gluconic; palmitic; oleic; lactic; pantothenic; and also penicillin salts.  The compounds may be prepared by condensing tetracycline or a salt thereof with at least 1 mole of formaldehyde or a source thereof, and about 1 mole of either 2,2-dimethylpyrrolidine or 1-azaspiro[4.5]decane, or salts thereof such as the hydrochloride.  The reaction is carried out in an inert solvent such as methanol, ethanol, or tertiary butanol, preferably with heating, with separation of the desired product, by cooling and filtration, or by lyophilizing the solution, or by addition of a non-solvent for the product, such as ether.  Examples are given for the preparation of the two compounds of the invention; the salts may be prepared by simple addition of the appropriate molar proportion of an acid to the compound.  The invention includes pharmaceutical compositions comprising a compound of the invention and a pharmaceutical carrier.
NEW MATERIAL:A compound expressed by formula I (R<1> is H or OH protecting group; R<2> is acryl; n>=1). EXAMPLE:A compound expressed by formula II. USE:A contraceptive. PREPARATION:A 6-hydroxy-17beta-estradiol derivative expressed by formula III is reacted with a benzoic acid derivative expressed by formula IV (X is OH or halogen) e.g. in a solvent in the presence of an organic base at room temperature-heated temperature for 1-10hr to provide the aimed compound expressed by formula I. The benzoic acid derivative is preferably used at an excess amount based on the compound expressed by formula III.
BACKGROUND: Chronic kidney disease (CKD) and end-stage renal disease (ESRD) have been associated with worse outcomes after transcatheter aortic valve replacement (TAVR). With TAVR indications extending to a wider range of patient populations, it is important to understand the current implications of chronic renal insufficiency on clinical outcomes. We aim to determine the impact of CKD and ESRD on in-hospital outcomes after TAVR.
METHODS: We queried the National Inpatient Sample for TAVR performed between 2016 and 2020 using International Classification of Diseases-10th Revision codes. We compared in-hospital mortality and clinical outcomes between three groups: normal renal function, CKD and ESRD. The association between CKD/ESRD and outcomes was tested with multivariable logistic regression analyses, using normal renal function as baseline.
RESULTS: In the five-year study period, 279,195 patients underwent TAVR (mean age 78.9 ± 8.5 years, 44.4% female). Of all patients, 67.1% had normal renal function, 29.2% had CKD, and 3.7% had ESRD. There were significant differences in age, sex, and prevalence of comorbidities across groups. In-hospital mortality was 1.3%. Compared to patients with normal renal function, patients with renal insufficiency had higher in-hospital mortality, with the highest risk found in patients with ESRD (adjusted odds ratio: 1.4 [95% confidence interval: 1.2-1.7] for CKD; adjusted odds ratio: 2.4 [95% confidence interval: 1.8-3.3] for ESRD). Patients with CKD or ESRD had a higher risk of cardiogenic shock, need for mechanical circulatory support, and vascular access complications, compared to those with normal renal function. In addition, patients with ESRD had a higher risk of cardiac arrest and periprocedural acute myocardial infarction. The incidence of conversion to open heart surgery was 0.3% and did not differ between groups. Post-procedural infectious and respiratory complications were more common among patients with CKD or ESRD.
CONCLUSION: Patients with CKD and ESRD are at higher risk of in-hospital mortality, cardiovascular, and non-cardiovascular complications after TAVR. The risk of complications is highest in patients with ESRD and does not result in more frequent conversion to open heart surgery. These results emphasize the importance of individualized patient selection for TAVR and procedural planning among patients with chronic renal insufficiency.
PURPOSE:The titled capsule having improved solubility and decay properties, obtained by blending gelating with a specific gelatin of succinogelatin. CONSTITUTION:Gelatin is blended with 50-100wt% succinogelatin. Some hard capsules like soft capsule often reduce solubility and decay properties by change with time, and some hard capsules are insolubilized as the result of chemical change when a certain drug (e.g., macrolide antibiotic) is packed into the capsules. Geltain is reacted with succinic anhydride, to give succinogelatin. When gelatin is treated with succinic anhydride, the amino group of amino acid, a constituent component for the gelatin, is blocked (acylated), attraction of both positive and negative ions between molecules is reduced, water molecules are apt to be easily permeated into the interior of gelatin, and decay properties are improved. On the other hand, atoms groups in the packed material can be bonded by the blocking of the amino group, so insolubilization phenomena caused by chemical bond between the capsules and the packed material can be prevented.
The antipsychotic drugs that patients took at baseline were prepared in unmarked capsules, with the dose adjusted to provide a 25% reduction weekly over the next 3 weeks. The dose tapering schedule was as follows: 3 capsules at baseline, 2 capsules at week 1, 1 capsule at week 2, and 0 capsules (i.e., the antipsychotic drugs were discontinued) at week 3. Clozapine was gradually increased to 300 mg/day according to the following schedule: 12.5 mg/day at day 0 and increased by 25 mg/day to 300 mg/day at day 12, with this dose maintained for three weeks and thereafter adjusted according to clinical judgment. Concomitant medications were kept constant throughout the study period.
The Coxib and traditional NSAID Trialists’ Collaboration meta-analysis of randomized controlled trials demonstrated an approximately two-fold increase in hospitalizations for heart failure in COX-2 selective-treated patients and nonselective NSAID-treated patients compared to placebo-treated patients. In a Danish National Registry study of patients with heart failure, NSAID use increased the risk of MI, hospitalization for heart failure, and death. 

Additionally, fluid retention and edema have been observed in some patients treated with NSAIDs. Use of flurbiprofen may blunt the CV effects of several therapeutic agents used to treat these medical conditions (e.g., diuretics, ACE inhibitors, or angiotensin receptor blockers [ARBs]) [ see Drug Interactions ( 7) ]. 

Avoid the use of flurbiprofen in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure. If flurbiprofen is used in patients with severe heart failure, monitor patients for signs of worsening heart failure.
Significance: Despite 20 years of research and new treatment methods, diabetic foot ulcer (DFU) remains a common problem with frequent recurrences and complications. Recent Advances: There are reports that nerve decompression (ND) surgery has been observed to produce significantly fewer DFU recurrences than standard of care (SOC). The explanation of this apparent superiority has not been understood. Critical Issues: Microcirculation is understood to be involved in diabetic peripheral neuropathy (DPN) and DFU. There is an underappreciation of the participation in DPN of entrapment neuropathy (EN) due to nerve swelling and impingement in fibro-osseous tunnels. Reducing c-fiber compression in EN by ND generates recovery of subepidermal capillary flow. ND studies have found improved neuromuscular function and epidermal microcirculation phenomena, including chronic capillary ischemia (CCI) and pressure-induced vasodilatation (PIV). There is no current therapy recommended for impaired microcirculation. Clinical and animal evidence has demonstrated that release of locally compressed peripheral nerves improves the epidermal microcirculation which is under sympathetic control. Future Directions: Using epineurolysis to relieve nerve compressions is a physiology-based therapeutic intervention and provides the scientific foundation clarifying how ND reduces DFU recurrence risk. Incorporating ND with current SOC treatments could improve DFU recurrence risk, hard-to-heal ulcers, neuroischemic wounds, amputation risk, and the resulting costs to society. More studies using ND for DFU, especially evidence-based medicine Level I studies, are needed to confirm these preliminary outcomes.